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Fasting reduces gastrointestinal cellular proliferation rates through G1 cycle blockade and can promote cellular
protection of normal but not cancer cells through altered cell signaling including down-regulation of insulin-like
growth factor 1 (IGF-1). Consequently, the purpose of this study was to determine the effects of fasting on
delayed-type chemotherapy-induced nausea and vomiting in dogs receiving doxorubicin. This prospective
randomized crossover study involved intended administration of two doses of doxorubicin. Cancer-bearing dogs
were randomized to be fasted for 24 hours beginning at 6 P.M. the night before the first or second doxorubicin
administration, and all treatments were administered within an hour before or after 12 P.M. Dogs were fed
normally before the alternate dose. Circulating IGF-1 concentrations were determined from serum samples
obtained immediately before each doxorubicin treatment. Data from 35 doses were available from 20 dogs
enrolled. Dogs that were fasted exhibited a significantly lower incidence of vomiting, when compared to fed
dogs (10% compared to 67%, P = .020). Furthermore, among the 15 dogs that completed crossover dosing,
vomiting was abrogated in four of five dogs that experienced doxorubicin-induced vomiting when fed normally
(P = .050). No differences in other gastrointestinal, constitutional, or bone marrow toxicities or serum IGF-1
levels were observed.
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Despite significant advances in anti-emetic drug therapy, chemotherapy-
induced nausea and vomiting (CINV) remains a significant problem in
the practice of clinical oncology [1]. CINV ranks among the most
distressing side effects of chemotherapy and therefore contributes to
patient non-compliance, treatment curtailment, and poor nutritional
status. CINV is commonly classified into one of three categories: acute-
onset CINV that occurs within 24 hours of initial administration of
chemotherapy, delayed-type CINV occurring 1 to 5 days after initial
treatment, and anticipatory CINV in patients whose emetic
episodes are triggered by senses, thoughts, or anxiety associated with
prior chemotherapy.Various mechanisms for delayed-type CINV have been proposed,
including disruption of the blood-brain barrier, disruption of
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of endogenous adrenal hormones, and accumulation of emetogenic
chemotherapy metabolites [2]. Damage to intestinal crypt cells after
exposure to cytotoxic drugs can result in delayed-type CINV through
release of 5-hydroxytryptamine 3, substance P, and cholecystokinin.
When bound to 5-hydroxytryptamine 3 and neurokinin-1 receptors,
these mediators stimulate the terminal ends of vagal afferents that
transmit signals to the vomiting center [3]. The considerable morbidity
associated with CINV has prompted prophylactic treatment with
serotonin antagonists, corticosteroids, dopamine antagonists, and
neurokinin-1 inhibitors to become commonplace in clinical practice.
Unfortunately, approximately 75% of human breast cancer patients still
report some symptoms of delayed-type CINV when treated with
doxorubicin-containing chemotherapy protocols [4,5]. Acute CINV
due to doxorubicin administration is also common in human patients
but is less frequent than the delayed type [5]. CINV has been reported
in 30% to 40% of dogs receiving doxorubicin but is almost exclusively
comprised of the delayed type, with one study reporting 91% of all
vomiting occurring after 48 hours [6].
Although doxorubicin is classified as a non–cell cycle–specific
agent, experimental studies have determined that selective lethal
cellular toxicity occurs when cells are in S-phase, whereas cells in G1
appear to be least sensitive [7–9]. Interestingly, animal studies have
determined that proliferative activity of gastrointestinal cells is subject
to circadian fluctuation that is largely driven by patterns of food
consumption [10]. Furthermore, studies have demonstrated that
fasting can dramatically reduce gastrointestinal cellular proliferation
rates through G1 cycle blockade, and refeeding of mice after a period
of fasting results in peak levels of S cellularity that can exceed four
times those of fasted mice [11].
Proliferative activity begins to decrease within 24 hours of
initiating fasting, and after refeeding, maximum proliferation
usually exceeds baseline in most tissues of the gastrointestinal
tract within 24 hours [10,11]. Taken together, these data provide
evidence that patterns of food consumption around the time of
chemotherapy administration could contribute to delayed-type
CINV in clinical cancer patients.
Fasting has also been shown to increase cellular resistance to stress,
inducing a protective effect on normal cells [12,13]. This protection is
believed to bemediated by reduced insulin-like growth factor 1 (IGF-1)
signaling and decreased activity of downstream effectors such as Akt,
Ras, and the mammalian target of rapamycin (mTOR) [12]. In normal
cells, this results in changes in gene expression and promotes resistance
to oxidative stress, thought to be one of the major mechanisms of
cytotoxicity caused by doxorubicin [14–16]. In contrast, it appears
that the cancer cell's inability to adapt to reduced nutrients
results in increased oxidative stress and cell death [17]. Therefore,
fasting-induced reduction in IGF-1 not only mediates the protective
effects on normal cells in vivo but is also implicated in the
chemotherapy sensitization of cancer cells [17,18]. Thus, fasting
may have the potential to modulate the therapeutic index of some
chemotherapy drugs.
A feasibility study recently reported 10 people voluntarily fasting
for 48 to 140 hours before treatment and for 5 to 56 hours after
receiving various different chemotherapeutic agents [19]. Minimal
adverse effects were described during fasting, and most subjects
maintained that fewer chemotherapy-related toxicities were experi-
enced after cycles for which they fasted at the time of treatment.
However, to the authors' knowledge, a formal prospective study hasnot evaluated the effects of fasting on delayed-type CINV. A reduced
incidence of anticipatory and acute CINV in dogs, both of which can
contribute to the delayed-type in people, makes the canine species
ideal for the study of delayed-type CINV. Herein, we report the
findings of a prospective, randomized study using a crossover design
to primarily evaluate the effects of fasting on delayed-type CINV in
cancer-bearing dogs. Because IGF-1 levels have been implicated as
playing an important role in selective chemosensitization in mouse
models and could have been affected by fasting, serum IGF-1
concentrations in both fasted and fed dogs were determined from
samples collected immediately before doxorubicin administration. The
effects of fasting on the incidence and severity of other commonly
observed doxorubicin-induced toxicities including diarrhea, decreased
activity, and bone marrow suppression were also evaluated.
Materials and Methods
Ethics Statement
The protocol and owner consent form were approved by the
University of California, Davis (UC Davis) Veterinary Medical
Teaching Hospital Clinical Trials Review Board (No. 11-11-10) in
accordance with campus policy regarding trials involving client-
owned dogs. Informed owner consent was obtained before
enrollment of all patients.
Patient Selection
Cancer-bearing dogs presenting to the UC Davis William R.
Pritchard Veterinary Medical Teaching Hospital (VMTH) between
February 2012 and June 2013, with the intention of pursuing at least
two doses of doxorubicin during the course of their chemotherapy
protocol were considered candidates for enrollment. All dogs received
an examination by a VMTH oncology clinician before enrollment.
To be included, dogs were required to have a physical examination
and weight recorded, in addition to a complete blood count (CBC)
and chemistry panel (performed within 2 weeks before enrollment).
Clinical chemistry panels and CBCs from veterinary clinics other than
the VMTH were considered acceptable.
Both therapy-naïve and patients in relapse after standard of care
were eligible for entry into this study. In addition, a favorable
performance status indicating a high likelihood of receiving two doses
of doxorubicin was necessary for inclusion. Dogs were required to be
fed twice daily (A.M. and P.M.), or be fed ad lib, as part of the
normal husbandry practices in the home. For entry into the study,
owners consented to feed a consistent diet throughout the duration
of the study.
Dogs were excluded if they had previously received doxorubicin
therapy, were believed to be at risk of the multidrug resistance gene-1
(MDR-1) mutation, were normally fed only once daily, experienced a
diet change within 1 week of treatment or showed signs of nausea,
vomiting, inappetence, or diarrhea within 2 days before receiving a
dose of doxorubicin. Dogs receiving concurrent medications with the
potential to alter gastrointestinal toxicosis, such as prednisone or
nonsteroidal anti-inflammatory drugs, were excluded unless they had
received this medication for a minimum of 2 weeks (1 week for
prednisone) before scheduled doxorubicin administration with no
reported gastrointestinal adverse effects, and they were anticipated to
stay on these medications for the duration of the study period. Dogs
with gastrointestinal tract involvement, suspicion of gastrointestinal
ulceration or brain metastasis, or pre-existing chronic gastrointestinal
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ciency were also excluded.
Treatment Protocol
All included dogs were intended to receive two doses of
doxorubicin at either 30 mg/m2 or 1 mg/kg as is standard of care,
depending on patient weight. Doxorubicin treatments were
administered at least 3 weeks apart. Dogs that remained on the
study for their second doxorubicin treatment received the same total
milligram dose as the first treatment. Doxorubicin was administered
as a 20-minute IV infusion. Pre-medication was given as is standard at
UC Davis at least 30 minutes before doxorubicin and included
dexamethasone (0.2 mg/kg, IV) for dogs not receiving oral prednisone
and diphenhydramine (2 mg/kg, IM or subcutaneously [SQ]) for
all dogs.
At the time of enrollment, dogs were randomized into one of two
feeding protocols (A or B). Randomization was performed by
selecting a blank envelope containing the dog's assignment from a
shuffled pile. A crossover design was used such that dogs in group A
were fed normally before their first dose of doxorubicin and then
fasted for their second dose. Conversely, dogs randomized to group B
were fasted for their first dose and then fed normally before their
second dose. When dogs were scheduled to fast, no food was given for
24 hours beginning at 6 P.M. the night before doxorubicin
administration. All dogs were treated within an hour before or after
12 P.M., and the time of infusion was recorded. A time discrepancy of
less than 2 hours between each of the treatments for each dog was
necessary for inclusion in the study.
A CBC with differential counts was scheduled 7 to 10 days after
each dose of doxorubicin. Additional hematologic and biochemical
parameters on each patient were measured throughout the study as
clinically indicated (CBC, chemistry panel, and urinalysis).
Concomitant medications for supportive care or other ongoing
medical conditions were allowed for patients enrolled in the study
except for prophylactic antiemetic or antidiarrheal drugs. Non-steroidal
anti-inflammatory drugs (NSAIDS) were allowed as long as the patient
had been on this medication for longer than 2 weeks before enrollment.
Dogs experiencing grade II or higher nausea or vomiting toxicity score
(according to the Veterinary Cooperative Oncology Group—Common
Terminology Criteria for Adverse Events [VCOG-CTCAE] v1.0) [20]
were treated as clinically indicated with either oral metoclopramide at a
target dose of 0.3mg/kg per os (PO) three times a day or ondansetron at
a target dose of 0.3 to 0.5mg/kg PO twice a day, depending on clinician
preference. The same antiemetic was to be used as required for the
duration of the study in each individual dog. Dogs that developed grade
II diarrhea were to be treated with oral metronidazole at a target dose of
10 to 15 mg/kg PO twice a day.
Dogs were removed from the study if a significant toxicity occurred
that precluded continuation of doxorubicin administration at the
same dose or if deemed to be clinically necessary for any other reason.
Dogs were removed from study at any time if review of the medical
record indicated a dog did not meet eligibility criteria, if a dog did not
receive the drug/agent at the prescribed dose, if progressive disease
occurred, if the dog required a significant diet change, or if the owner
requested withdrawal from the trial for any reason.
As was required at UC Davis for client-owned animals, the
study design and treatment protocol were evaluated by the
Clinical Trials Review Board at the UC Davis VMTH and were
granted approval.Response and Toxicity Assessment
One week after each dose of doxorubicin, owners were asked to
score their pet's toxicity on a visual analog scale similar to that
reported in Rau et al. [6]. Gastrointestinal toxicity was scored by the
owners 1 week after administration of doxorubicin using the visual
analog scale as previously published [6]. The mark placed by owners
on each scale was given a number between 0 and 4 and corresponded
to the VCOG-CTCAE v1.0 toxicity scoring [20]. If owners marked
between whole numbers, then a value equal to the proportion along
the scale was given. Neutropenia and thrombocytopenia were assessed
from CBC values obtained 7 to 10 days after doxorubicin
administration and given a grade using the VCOG-CTCAE v1.0
scheme [20]. Gastrointestinal, constitutional, and hematologic
variables were evaluated as both continuous and categorical data.
Each mark corresponded to a score from the VCOG-CTCAE v1.0
scheme, yielding a numerical value from 0 (no toxicity) to 4 (life
threatening toxicity). Specific categories assessed included appetite,
nausea, vomiting, diarrhea, and activity. The owner of one dog
performed daily evaluations of toxicity rather than one evaluation at
the end of the week. In this case, the highest score for each category
was assigned for that dose. In the one dog that was hospitalized due to
toxicity, scores were recorded based on the owner's evaluation but
were then updated with information from the medical record during
the hospital stay.
Bone marrow toxicity was scored using CBC results obtained 7 to
10 days after each dose of doxorubicin according to the VCOG-
CTCAE v1.0 criteria for neutropenia and thrombocytopenia.
Serum IGF-1 Measurement
Blood samples (~3.0 ml) were obtained by jugular venipuncture
before doxorubicin treatment. Samples were allowed to clot and were
then centrifuged, enabling serum to be drawn off and promptly
frozen at −80°C until analysis. Samples were stored in this manner
until all were collected. Serum IGF-1 concentrations were measured
using an IGF-1 ELISA (ALPCODiagnostics, Salem, NH). This assay
uses two specific and high affinity antibodies against human IGF-1. The
first is coated on the 96-well microtiter plate, to which the serum sample
was added. The second is biotinylated, resulting in color development
after the addition of streptavidin-peroxidase-enzyme conjugate that was
proportional to the IGF-1 level in the serum sample.
Statistical Analysis
Statistical analyses consisted of Fisher exact and exact Mann-
Whitney tests on first dose toxicity data. For paired data, the
McNemar test and the Wilcoxon-signed rank test were used to
evaluate incidence and severity of toxicity, respectively.
Results
Twenty-seven client-owned, cancer-bearing dogs were enrolled
(Figure 1). Six dogs were withdrawn from the study after
randomization but before administration of any doxorubicin. One
of these six dogs was removed due to the finding of preexisting
cardiotoxicity, one was euthanized before receiving doxorubicin, two
owners were non-compliant with the feeding protocol, and the
remaining two dogs developed concurrent illness before doxorubicin
administration that precluded their involvement in the study. In
addition, one dog was euthanized due to disease progression shortly
after receiving the first dose of doxorubicin before toxicity data could
be collected.
Figure 1. Enrollment and exclusions. Flow chart provides details on
dogs enrolled and exclusions from measured end points.
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successfully crossed over and completed the second intended dose of
doxorubicin on the study. Consequently, 15 dogs had complete
gastrointestinal toxicity data available for both “fed” and “fasted”
treatments. These dogs were represented by six from group A (fed
first, fasted second) and nine from group B (fasted first, fed second).
Of the five dogs for which data were available for one dose of
doxorubicin only, four dogs were in group A with three being
withdrawn after the first “fed” dose. The remaining dog in group A
had recorded toxicity data from the second fasted dose only. One of
these five dogs with only one data set was randomized to group B and
was subsequently withdrawn after the first fasted dose. Figure 1
outlines the reasons for lack of complete data from these five dogs. In
each group, A and B, similar characteristics were observed in regards
to age, sex, weight, breed, and tumor type (Table 1). All 20 dogs had
lymphoma, and patient details reflected that of previous reports on
dogs with this cancer type [21]. In addition, there were similar
proportions of dogs receiving doxorubicin at the 1 mg/kg dose and
30 mg/m2 dose between group A and group B.Table 1. Patient Characteristics of Dogs in Group A (Fed First) Compared to Dogs in Group B
(Fasted First).
Characteristics All Group A Group B
Number 20 10 10
Age (years) Median 7.5 9 7
Range 3-14 5-14 3-12
Sex MC 11 6 5
FS 7 3 4
F 2 1 1
Weight (kg) Median 24.4 23.85 27.1
Range 3.9-38.8 9.5-38.8 3.9-37.3
Breed Mix 10 5 5
Welsh Corgie 2 2 0
Lab 2 1 1
Basset Hound 2 1 1
Other 4 1 3
Tumor type Lymphoma (B cell) 14 8 6
Lymphoma (T cell) 4 1 3
Lymphoma (unknown) 2 1 1
Doxorubicin dose 1 mg/kg 9 5 4
30 mg/m2 11 5 6Since dogs could be withdrawn from the study due to excessive
toxicity after their initial treatment, we first wanted to analyze
toxicities experienced by all dogs after their first dose. It was suspected
that an inherent bias toward study withdrawal could occur in dogs
experiencing toxicity after the first dose; therefore, bias might occur if
in fact dogs in one group were more likely to experience delayed-type
CINV. In fact, of the three dogs in group A that were removed from
the study after their first dose, all three experienced vomiting after this
initial “fed” dose. The dog in group B (fasted first) that was
withdrawn did not experience vomiting after this first dose. Included
in this initial analysis were 9 dogs that were fed before their first
treatment (group A dogs) and 10 dogs that were fasted before their
first treatment (group B dogs; Table 2). A significant difference
between vomiting incidence in dogs was observed, with 6 of 9 (67%)
fed before treatment experiencing vomiting compared to 1 of 10
(10%) that fasted (P = .020). Of those who were fed before treatment,
vomiting scores consisted of three dogs with grade 0.5, two dogs with
grade 1, and one dog with grade 3 vomiting on a continuous scale.
The single dog that vomited after fasting before administration had
grade 1 toxicity. Interestingly, the owner of this dog reported that the
animal had eaten trimmings of horse hooves before the episode on day
5 after receiving doxorubicin. The difference in mean vomiting scores
between dogs fed and fasted before their first treatment was also
found to be significant (0.72 compared to 0.10, P = .017).
Paired data were then evaluated from the 15 dogs for which it was
available. Given the likelihood of a bias among these dogs toward
individuals that were less likely to vomit (given their continued
presence on the study after their first dose), we were most interested in
the dogs whose toxicity changed between treatments. Ten of 15 dogs
did not exhibit vomiting after being fasted or fed. Among the five
dogs that vomited, one dog vomited after both fasted and fed doses,
and the remaining four dogs vomited only when fed before treatment
(P = .050). Of these four dogs, three were in group A and one in
group B. However, the majority of dogs exhibited only mild vomiting
and there was no significant difference in severity of vomiting (P = .31).
When nausea incidence was evaluated between dogs fed and those
fasted before their first dose, 4 of 9 (44%) that were fed and 4 of 10
(40%) that were fasted experienced nausea. This difference was not
statistically significant (P = 1). Nausea scores after the first dose of
doxorubicin in dogs that were fed included one dog with grade 1, twoTable 2. Toxicity Data.
First Dose Data Crossover Data
Fed Fasted P Value Fed Fasted P Value
Toxicity
(%) (%) Incidence Scores (%) (%) Incidence Scores
Vomiting 6/9 1/10 .020 .017 5/15 1/15 .050 .313
(67) (10) (33) (6.7)
Nausea 4/9 4/10 1.000 .810 6/15 6/15 1.000 .531
(44) (40) (40) (40)
Appetite 3/9 3/10 1.000 .703 5/15 5/15 1.000 1.000
(33) (30) (33) (33)
Diarrhea 7/9 7/10 1.000 .103 6/15 10/15 .130 .613
(78) (70) (40) (67)
Activity 6/9 8/10 .629 .636 7/15 10/15 .540 .672
(67) (80) (47) (67)
Neutropenia 4/9 1/10 .141 .098 4/14 4/14 1.000 1.000
(44) (10) (29) (29)
Thrombocytopenia 3/9 1/10 .303 .512 3/14 2/14 .700 1.000
(33) (10) (21) (14)
Mean IGF-1 (ng/ml) 183 164 .910
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fasted before their first dose, nausea scores reported were two dogs
with grade 1 and one dog each with grade 2 and grade 4 toxicity. No
significant difference in nausea scores was observed (P = .81).
Additionally, no difference in the incidence of nausea or nausea scores
was detected when evaluating all paired data (Table 2).
Second, we evaluated the difference in other gastrointestinal and
constitutional toxicity observed between treatments when dogs were
fed and fasted. No significant difference between the incidence and
scores of appetite, diarrhea, or activity was evident between
treatments when first dose or paired data were analyzed (Table 2).
Similarly, no differences in the incidence or scores of neutropenia or
thrombocytopenia were detected (Table 2). Lastly, there was no
significant difference in IGF-1 concentration between when dogs
were fed or fasted before treatment (Table 2 and Figure 2).
Discussion
To the authors' knowledge, this study is the first randomized
prospective clinical evaluation of the effects of fasting on the incidence
of CINV in cancer-bearing patients. Here, we reported our findings
assessing the impact of fasting for 18 hours before and 6 hours after
doxorubicin chemotherapy in cancer-bearing dogs. Our data suggest
that fasting for 24 hours significantly reduces the incidence of
vomiting in dogs treated with doxorubicin but did not appear to affect
nausea or other potential adverse effects commonly seen in
doxorubicin-treated cancer-bearing dogs.
The effect of fasting on the modulation of digestive tract cellular
proliferation has long been known [10,11]. Theoretically, by blocking
gastrointestinal cells in the G1 phase with fasting, these cells should be
less sensitive to the effects of doxorubicin, which is preferentially toxic
to cells in the S phase [8,9]. In addition to the effects of fasting on the
cell cycle, it also appears that protection is elicited in part by other
mechanisms that likely alter gene expression [18]. In one study,
protection of mice from doxorubicin toxicity by fasting before
treatment appeared to be mediated by a reduction in circulating IGF-
1 levels such that administration of IGF-1 abolished the protective
effect of fasting [18]. Furthermore, mouse embryonic fibroblastsFigure 2. IGF-1 concentration changes. Pretreatment serum IGF-1
levels were determined by ELISA. Each line represents the change
in IGF-1 concentration for an individual dog between “fed” and
“fasted treatments.grown to confluence in vitro and then treated with doxorubicin were
found to be protected from cell killing by IGF-1 receptor deletion
compared to cells that overexpressed IGF-1 receptor [18]. In this case,
the proliferation rate was kept relatively constant by the confluence of
the cells in culture and therefore cytoprotection appeared to be
independent of the cell cycle.
Supporting the notion that fasting before chemotherapy might
result in reduced clinical toxicity are several studies in mice illustrating
that cellular stress resistance is elicited by fasting [13,18]. In one
report, etoposide administered at 80 mg/kg killed 43% of control
mice compared to 6% of mice that were fasted for 48 hours before
administration [13]. Reduced IGF-1 signaling was also found to
protect primary glia but not glioma cells against high-dose
cyclophosphamide in vitro, supporting the notion of differential
stress resistance, whereby normal cells but not cancer cells experience
this protective effect [18]. Recently, fasting cycles alone have also
been shown to cause cytotoxicity and chemotherapy sensitization of
cancer cells in vitro and in mouse models [17].
In a feasibility study reporting on 10 people with various cancer
types and stages, who had voluntarily fasted for 48 to 140 hours
before and for 5 to 56 hours after chemotherapy, patient complaints
during fasting included mild dizziness, hunger, and headaches, which
did not interfere with daily function [19]. Any weight loss was rapidly
recovered after cessation of fasting. All 10 human patients who
undertook fasting around the time of treatment described the lack of
nausea, vomiting, diarrhea, abdominal cramps, and mucositis after
cycles of chemotherapy. At least one of these symptoms was reported
in five of six patients after cycles where no fasting was performed [19].
While the previous study showed that fasting was feasible and safe in
human cancer patients receiving chemotherapy, it was not a
prospective design and the exceedingly long fasting periods seem
unlikely to be acceptable for many patients in clinical practice.
Dogs may serve as an excellent model to study the clinical
applications of fasting to ameliorate delayed-type CINV in cancer
patients. The relative lack of doxorubicin-associated anticipatory and
acute CINV in dogs, compared with people, ensures that delayed-
type CINV specifically can be studied in dogs without any
appreciated cumulative effects of the other two types, as occurs in
people [2]. Furthermore, client-owned dogs are more likely to have a
consistent diet, allowing minimal variation in potentially confound-
ing factors between doses within each patient. People, in the absence
of fasting, have a much more diverse diet and individuals possess the
ability to decide the type, frequency, and amount of food consumed
on any particular day.
When all available first dose data were analyzed alone, a significant
increase in vomiting incidence and severity was observed in dogs that
were fed (67% incidence) compared to dogs that were fasted before
doxorubicin treatment (10% incidence). The limitations of this
analysis however is that without longitudinal paired data (i.e., data
from a “fasted” and a “fed” dose in the same dog), we lose the internal
control values for each dog. This leaves our data open to confounding
from an immeasurable number of variables that might increase or
decrease each dog's risk of vomiting. However, if dogs were more
likely to have experienced toxicity after doxorubicin when they were
fed normally, it is possible that dogs randomized to group A (fed first)
would be more likely to be withdrawn from the study before their
second dose than dogs in group B. Removal of these dogs that
vomited after their first dose would exclude them from the paired
analysis completely, perhaps creating a bias toward group A dogs that
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withdrawn from the study before their second dose, three were fed
first and all three experienced vomiting. While we saw a higher
incidence of vomiting in dogs fed before their first doxorubicin dose
when compared to historical reports with this agent, feeding was not
standardized in previous studies. When all dogs in our study were
evaluated together, the overall incidence of vomiting in 19 dogs for
which first dose data were available was 36.8% (7 of 19) and is similar
to data from dogs receiving placebo in a previous prospective
randomized study [6].
In our paired data, the incidence of gastrointestinal and
constitutional side effects after “fed” (control) doses of doxorubicin
was similar to that previously reported when evaluated in a similar
manner [6]. While 33% of dogs vomited after the “fed” treatment
(5 of 15), only 6.7% (1 of 15) of dogs vomited after the “fasted”
treatment. In other words, fasting appeared to abrogate vomiting in
four of five dogs that otherwise vomited when they were fed normally
before doxorubicin treatment. It was interesting that in the only dog
that experienced vomiting after being fasted the owner noted that this
was likely secondary to dietary indiscretion (dog had eaten horse hoof
trimmings). While the authors considered that dietary indiscretion
could warrant exclusion from analysis, it was felt that exclusion of this
case was not justified and might inappropriately bias the results.
Interestingly, despite the difference in vomiting incidence between
dogs fed and fasted before doxorubicin treatment, the incidence of
inappetence, nausea, diarrhea, and lethargy appeared to be very
similar between treatments. The reason for this inconsistency is
unknown. A plausible argument for the lack of change in nausea and
lethargy would simply be that owners often struggle to accurately
observe changes in these subjective signs, resulting in only the
objective aberrations being noted. Similar to our findings, Rau et al.
reported no perceived reduction in nausea incidence or severity with
prophylactic maropitant administration, despite significant decreases
in vomiting [6]. It is also possible that some parts of the
gastrointestinal tract may be more or less susceptible to the protective
state induced by fasting. In mice, colonic mucosa does appear to
respond to refeeding by increasing proliferation above baseline
feeding rates in a much more exaggerated manner than mucosa of the
jejunum and ileum [11]. However, these peak proliferation rates
reach their maximum around 24 hours after refeeding, which would
be approximately 30 hours after doxorubicin administration in our
dogs. While some doxorubicin is likely still present in serum at that
time due to a terminal elimination half life of around 20 hours, the
concentration is very low [22]. To the authors' knowledge, differences
in stress resistance elicited by fasting in various anatomic locations
have not been thoroughly determined. Nevertheless, it is quite
possible that the timing of refeeding after fasting may be critical. In
contrast, the case series including 10 human cancer patients described
reduced nausea, vomiting, and diarrhea with fasting before
chemotherapy [19]. Although, patient self-reporting of side effects
raises the possibility of bias or placebo effect in human patients
volunteering for such a study. No effect of fasting on myelotoxicity
was expected, and although we evaluated only a limited number of
patients at a single time point, our results failed to show any
significant differences in neutropenia or thrombocytopenia between
“fed” and “fasted” treatments.
Circulating IGF-1 levels have been found to negatively correlate
with the protective effect of 72-hour fasting against chemotherapy
toxicity in mice [18]. In rats, IGF-1 concentration begins to dropafter 24 hours of fasting, but significant decreases from baseline are
not apparent until 48 hours [23]. As previously discussed, alterations
in cell cycle and decreased IGF-1 signaling have both been implicated
as mechanisms for differential stress resistance in mouse models
[17,18]. However, their individual or collective contributions to
CINV simply cannot be accurately evaluated in murine models that
do not exhibit vomiting. Using clinical canine patients, we observed a
significant difference in the incidence of vomiting in dogs that were
fasted when compared to fed dogs. However, in the measurement of
serum IGF-1 using an ELISA as has previously been reported in dogs
[24,25], we found no significant difference in serum IGF-1
concentration in dogs with paired data from both “fed” and “fasted”
treatments, which is in agreement with two previous canine studies
that have reported that fasting for 18 to 20 hours does not alter serum
IGF-1 or IGFBP concentrations [26,27]. The lack of a significant
decrease in IGF-1 levels in our dogs after an 18-hour fast suggests that
extending the duration of fasting might be necessary to significantly
reduce the IGF-1 concentration before chemotherapy and conse-
quently to see a maximum clinical benefit. However, the reduction in
vomiting incidence despite the lack of a significant decrease in serum
IGF-1 concentration may indicate that this effect is independent of
IGF-1 signaling.
A limitation of our study is the small sample size. This may have
resulted in insufficient power to prove a significant difference in toxicity
in the 15 dogs with paired data. The predominant reason most owners
gave for declining enrollment in the trial was the perception that
withholding food from their dog would cause them (their dog and
frequently also the owner) distress. Therefore, while most studies
suggest that fasting for longer than 24 hours is necessary to observe
maximum protection against toxicity, this may be difficult clinically
without thorough elucidation and education of the potential benefits.
Our study did not attempt to investigate the potential therapeutic
effects of fasting on tumor control and chemotherapy sensitization,
although clinical studies evaluating this in the future may be
warranted. Data from this report, however, would suggest that a
lengthier fasting period is necessary in dogs to significantly reduce
circulating IGF-1 levels and possibly elicit the therapeutic effect that
has been suggested in murine studies. In addition, clinical studies
evaluating the benefit of fasting in reducing toxicity from other
chemotherapy agents are critical. Importantly, some chemotherapy
agents such as those in the platinum family possess the greatest
cytotoxic effect when exposure is in the G1 phase and thus could
cause increased toxicity to intestinal epithelial cells. In such a case,
fasting could differentially increase CINV for this class of agents
[8,28]. Furthermore, investigation into any potential additive effect of
fasting combined with prophylactic antiemetic therapy is necessary to
determine if this protective effect can be enhanced further, especially
since prophylactic antiemetic therapy is routinely prescribed.
Delayed-type CINV remains a significant concern for both human
and canine cancer patients. Our findings suggest that fasting for 18
hours before and 6 hours after doxorubicin chemotherapy reduces the
risk of vomiting in doxorubicin-treated cancer-bearing dogs. When
first dose data alone were reviewed, a significantly reduced vomiting
incidence and severity were detected in dogs fasted before treatment
compared to those that were fed. While it is clear that many dogs
vomited neither after the “fed” nor the “fasted” doses, analysis of
paired data revealed that in dogs that vomited after only one dose, this
tended to be from the “fed” dose. Taken together, these data suggest
that some dogs may benefit from fasting before doxorubicin,
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contend that the dog serves as an excellent model to further
investigate the optimal parameters and clinical efficacy of fasting for
reduction of chemotherapy side effects in people.
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